<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01439347</url>
  </required_header>
  <id_info>
    <org_study_id>TTX404</org_study_id>
    <nct_id>NCT01439347</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL</brief_title>
  <official_title>Phase 3 Study of Study to Evaluate Marqibo® in the Combination Chemotherapy in the Treatment of Subjects &gt;or=60 Years Old With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spectrum Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 3 study in the treatment of subjects &gt;or= 60 years old with newly diagnosed acute
      lymphoblastic leukemia (ALL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase 3, multicenter, randomized study to evaluate the substitution of Marqibo®
      (Vincristine Sulfate Liposomes Injection, VSLI) for standard Vincristine Sulfate Injection
      (VSI) in the induction, intensification, and maintenance phases of combination chemotherapy
      in the treatment of subjects &gt;or= 60 years old with newly diagnosed acute lymphoblastic
      leukemia (ALL).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor decision
  </why_stopped>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Efficacy Criterion</measure>
    <time_frame>24 months of Sequential Induction</time_frame>
    <description>Overall Survival will be measured for all subjects from the date of randomization until death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Criteria</measure>
    <time_frame>Complete Remission</time_frame>
    <description>Complete remission )CR+CRi; best response during study Duration of Response (CR+CRi) Event Free Survival(EFS)will be measured from the date of randomization until the date of the earliest of the following events: Death from any cause, relapse from CR/CRi, Bone marrow and or blood examination documentation failure to achieve CR/CRi following the last course of radiation therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Acute Lymphoblastic Leukemia (ALL)</condition>
  <arm_group>
    <arm_group_label>Vincristine Sulfate Injection (VSI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This is a phase 3, international, multicenter, open-label randomized, controlled trial with 2 treatment arms that vary only in the administration of standard VSI vs. Marqibo. Eligible subjects will be randomized to combination chemotherapy containing either VSI or Marqibo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Marqibo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administration of standard VSI vs. Marqibo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine Sulfate Liposomes Injection (VSLI)</intervention_name>
    <description>2.25 mg/m2 (without any dose cap) as an IV infusion over 60 minutes</description>
    <arm_group_label>Marqibo</arm_group_label>
    <other_name>Marqibo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine Sulfate Injection (VSI)</intervention_name>
    <description>1.4 mg/m2 with a 2 mg dose cap as an intravenous (IV) infusion over 10 minutes</description>
    <arm_group_label>Vincristine Sulfate Injection (VSI)</arm_group_label>
    <other_name>Vincristine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Have provided written, signed, and dated informed consent to participate in the study, in
        accordance with the ICH GCP Guideline E6 and all applicable local regulations.Are age
        &gt;or=60 years (at the time of providing informed consent).

        Have newly diagnosed, histologically proven, untreated Philadelphia chromosome-negative
        (Ph-) ALL, with &gt;or= 5% bone marrow blasts.

        Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Have a life
        expectancy &gt;or= 3 months.

        Have renal and liver function as defined below within 14 days, inclusive, prior to study
        enrollment, unless the abnormality is considered attributable to leukemia:

        Total bilirubin ≤ 2.0 x the upper limit of normal (ULN), unless the subject has a known
        diagnosis of Gilbert's disease Aspartate transaminase (AST, SGOT) or alanine transaminase
        (ALT, SGPT) ≤ 3 x ULN Serum creatinine ≤ 1.5 x ULN. Not have had major surgery within 4
        weeks before the planned start of treatment.

        If female, are post-menopausal, surgically sterilized, or willing to use acceptable methods
        of birth control (eg, hormonal contraceptive, intra-uterine device, diaphragm with
        spermicide, condom with spermicide, or abstinence) from the screening visit through 30 days
        after the last dose of any protocol defined chemotherapeutic agents.

        If male and sexually active with a partner of child-bearing potential, agree to use an
        acceptable barrier method for contraception from the screening visit through 30 days after
        the last dose of any protocol defined chemotherapeutic agents.

        Have the ability and willingness to fully comply with study procedures and restrictions.

        Exclusion Criteria:

        Has had prior systemic chemotherapy (for ALL or other malignancy). Has had prior
        vincristine for any reason. Is planning to undergo stem cell transplantation (SCT) as any
        part of first-line therapy for ALL.

        Has Burkitt's lymphoma/leukemia. Has Philadelphia chromosome-positive (Ph+) ALL and/or
        BCR/ABL rearrangements documented by fluorescent in-situ hybridization (FISH),
        cytogenetics, or polymerase chain reaction (PCR).

        Has active central nervous system (CNS) disease. Has ongoing neuropathy of any etiology &gt;
        Grade 1. Has a history of persistent active neurologic disorders including demyelinating
        form of Charcot-Marie-Tooth syndrome, acquired demyelinating disorders, and other
        demyelinating conditions.

        Prior hydroxyurea (Hydrea®) for the management of any condition other than leukocytosis or
        prior hydroxyurea of &gt;7 days duration for the management of leukocytosis (hydroxyurea for
        the management of leukocytosis must be planned to be tapered off before or on Day 5 of
        Induction).

        Has received prior steroids within 7 days before beginning protocol-specified Induction
        therapy for reasons other than leukocytosis (steroids for the management of leukocytosis
        are allowed but must be planned to be tapered off before or on Day 5 of Induction).

        Has an active serious infection not controlled by oral or IV antibiotics or antifungals.

        Has received any investigational therapy within 28 days before beginning any
        protocol-defined chemotherapeutic treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan M O'Brien, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MD Anderson</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University, Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Fienberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110-1093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-7680</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas, M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston, Texas</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2011</study_first_submitted>
  <study_first_submitted_qc>September 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2011</study_first_posted>
  <last_update_submitted>July 20, 2016</last_update_submitted>
  <last_update_submitted_qc>July 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Marqibo</keyword>
  <keyword>HALLMARQ</keyword>
  <keyword>leukemia</keyword>
  <keyword>front-line</keyword>
  <keyword>ALL</keyword>
  <keyword>acute lymphoblastic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

